Earnings call briefSecond-quarter 2026
Bristol-Myers Squibb now expects milvexian AFib readout in first quarter 2027
The company said slower event accrual drove the milvexian change, and slower enrollment and relapse events drove the ADEPT change.
GetSignal Bristol-Myers Squibb BMY
Bristol-Myers Squibb said on its second-quarter call that it now expects the milvexian atrial fibrillation study to read out in the first quarter of 2027, from late 2026.
It also said the top-line readouts from the ADEPT program for Cobenfy in Alzheimer's psychosis are now expected to begin in early 2027 and spread across the year.
Quotes from the call
“For milvexian, we now expect the atrial fibrillation study to read out in the first quarter of 2027.”
Key facts from the call
- Expected milvexian AFib readout
- First quarter 2027, previously late 2026
- Expected ADEPT top-line readouts
- Begin early 2027, spread across the year
Source: Bristol-Myers Squibb's second-quarter 2026 earnings call, July 30, 2026.
Written by GetSignal with AI from the company's earnings call.
Not investment advice.
More earnings call briefs
- Bristol-Myers Squibb says it now expects legacy portfolio revenue down 3% to 5%
BMY Bristol-Myers Squibb Q3 2026 call
- Constellation Energy expects nuclear uprate costs of about $4.3 billion
CEG Constellation Energy Q3 2026 call
- Howard Hughes Holdings says its insurance ambition is a return on equity in excess of 20%
HHH Howard Hughes Holdings Q3 2026 call
- Brookfield Asset Management now sees 2026 earnings modestly below early view
BAM Brookfield Asset Management Q3 2026 call
- Enbridge says it expects 2026 results at the midpoint of its guidance range
ENB Enbridge Q3 2026 call
